Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer

Molecularly targeted therapies are rapidly growing with respect to their clinical development and impact on cancer treatment due to their highly selective anti-tumor action. However, many aggressive cancers such as triple-negative breast cancer (TNBC) currently lack well-defined therapeutic targets against which such agents can be developed. The identification of tumor-associated antigens and the generation of antibody drug-conjugates represent an emerging area of intense interest and growth in the field of cancer therapeutics. Glycoprotein non-metastatic b (GPNMB) has recently been identified as a gene that is over-expressed in numerous cancers, including TNBC, and often correlates with the metastatic phenotype. In breast cancer, GPNMB expression in the tumor epithelium is associated with a reduction in disease-free and overall survival. Based on these findings, glembatumumab vedotin (CDX-011), an antibody-drug conjugate that selectively targets GPNMB, is currently being investigated in clinical trials for patients with metastatic breast cancer and unresectable melanoma. This review discusses the physiological and potential pathological roles of GPNMB in normal and cancer tissues, respectively, and details the clinical advances and challenges in targeting GPNMB-expressing malignancies.

[1]  M. Marks,et al.  The PKD domain distinguishes the trafficking and amyloidogenic properties of the pigment cell protein PMEL and its homologue GPNMB , 2013, Pigment cell & melanoma research.

[2]  K. Ariizumi,et al.  The DC‐HIL ligand syndecan‐4 is a negative regulator of T‐cell allo‐reactivity responsible for graft‐versus‐host disease , 2013, Immunology.

[3]  A. Stopeck,et al.  Abstract P6-10-01: A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study , 2012 .

[4]  T. Dandekar,et al.  Identification of New Therapeutic Targets by Genome-Wide Analysis of Gene Expression in the Ipsilateral Cortex of Aged Rats after Stroke , 2012, PloS one.

[5]  J. Fallowfield,et al.  Edinburgh Research Explorer Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis Differential Ly-6C expression identi fi es the recruited macrophage phenotype, which orchestrates the regression of murine liver fi brosis , 2022 .

[6]  K. Tsui,et al.  Glycoprotein transmembrane nmb: An androgen‐downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells , 2012, The Prostate.

[7]  Jian-Zhong Zhang,et al.  Expression of glycoprotein non-metastatic melanoma protein B in cutaneous malignant and benign lesions: a tissue microarray study. , 2012, Chinese medical journal.

[8]  Kerry A Chester,et al.  Antibody–drug conjugates – a perfect synergy , 2012, Expert opinion on biological therapy.

[9]  T. Gao,et al.  Silencing of GPNMB by siRNA Inhibits the Formation of Melanosomes in Melanocytes in a MITF-Independent Fashion , 2012, PloS one.

[10]  G. Sobue,et al.  The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis , 2012, Scientific Reports.

[11]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[12]  A. Børresen-Dale,et al.  The Life History of 21 Breast Cancers , 2012, Cell.

[13]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[14]  S. Mohan,et al.  Targeted Overexpression of Osteoactivin in Cells of Osteoclastic Lineage Promotes Osteoclastic Resorption and Bone Loss in Mice , 2012, PloS one.

[15]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[16]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[17]  C. Susin,et al.  Exploratory study on the effect of osteoactivin on bone formation in the rat critical-size calvarial defect model. , 2012, Journal of periodontal research.

[18]  S. Yokoyama,et al.  Expression and immunolocalization of Gpnmb, a glioma-associated glycoprotein, in normal and inflamed central nervous systems of adult rats , 2012, Brain and behavior.

[19]  P. Brossart,et al.  The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors , 2012, Cancer Immunology, Immunotherapy.

[20]  C. Keir,et al.  The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer , 2012, Expert opinion on biological therapy.

[21]  Q. Chu,et al.  Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer , 2011, International journal of breast cancer.

[22]  Alan D. Lopez,et al.  Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis , 2011, The Lancet.

[23]  V. Kataja,et al.  Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study , 2011, Breast Cancer Research.

[24]  I. Pastan,et al.  Affinity‐matured anti‐glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas , 2011, International journal of cancer.

[25]  A. Tutt,et al.  Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. , 2011, Cancer discovery.

[26]  K. Ariizumi,et al.  Inhibition of T‐cell activation by syndecan‐4 is mediated by CD148 through protein tyrosine phosphatase activity , 2011, European journal of immunology.

[27]  S. Adler,et al.  Hematopoietic growth factor inducible neurokinin-1 (Gpnmb/Osteoactivin) is a biomarker of progressive renal injury across species. , 2011, Kidney international.

[28]  Bing Li,et al.  The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair. , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  Mark T. W. Ebbert,et al.  A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[30]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[31]  F. Pépin,et al.  ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic Properties , 2010, PloS one.

[32]  J. M. Bradshaw,et al.  The Src, Syk, and Tec family kinases: distinct types of molecular switches. , 2010, Cellular signalling.

[33]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[34]  K. Ariizumi,et al.  DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. , 2010, Cancer research.

[35]  Alberto Mantovani,et al.  Tumor-Conditioned Macrophages Secrete Migration-Stimulating Factor: A New Marker for M2-Polarization, Influencing Tumor Cell Motility , 2010, The Journal of Immunology.

[36]  Suzanne F. Jones,et al.  Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE). , 2010 .

[37]  P. Hwu,et al.  Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. , 2010 .

[38]  Victor L. J. Tybulewicz,et al.  The SYK tyrosine kinase: a crucial player in diverse biological functions , 2010, Nature Reviews Immunology.

[39]  V. Hearing,et al.  Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome‐specific and proteolytically released protein , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  L. Naumovski,et al.  Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. , 2010, Current opinion in molecular therapeutics.

[41]  P. Pokarowski,et al.  Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. , 2010, The American journal of pathology.

[42]  M. Hallett,et al.  Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer , 2010, Clinical Cancer Research.

[43]  Gordon D. Brown,et al.  Syk‐coupled C‐type lectin receptors that mediate cellular activation via single tyrosine based activation motifs , 2010, Immunological reviews.

[44]  D. Benjamin,et al.  Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate , 2010, Clinical Cancer Research.

[45]  L. Hart,et al.  A Phase (Ph) I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients (Pts) with Locally Advanced or Metastatic Breast Cancer (MBC). , 2009 .

[46]  K. Ariizumi,et al.  Binding of DC-HIL to Dermatophytic Fungi Induces Tyrosine Phosphorylation and Potentiates Antigen Presenting Cell Function1 , 2009, The Journal of Immunology.

[47]  Edward L. Lee,et al.  Distinct High-Profile Methylated Genes in Colorectal Cancer , 2009, PloS one.

[48]  K. Ariizumi,et al.  Gpnmb is a melanosome‐associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD‐dependent fashion , 2009, Experimental dermatology.

[49]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[50]  P. Hwu,et al.  GPNMB expression in uveal melanoma: a potential for targeted therapy , 2010, Melanoma research.

[51]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[52]  Lionel B Ivashkiv,et al.  Cross-regulation of signaling by ITAM-associated receptors , 2009, Nature Immunology.

[53]  C. Perou,et al.  Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  V. Hearing,et al.  Physiological factors that regulate skin pigmentation , 2009, BioFactors.

[55]  T. Wolfsberg,et al.  Gpnmb is a melanoblast‐expressed, MITF‐dependent gene , 2009, Pigment cell & melanoma research.

[56]  A. Selim.  Osteoactivin bioinformatic analysis: prediction of novel functions, structural features, and modes of action. , 2009, Medical science monitor : international medical journal of experimental and clinical research.

[57]  M. Namer,et al.  Prognostic factors in 1,038 women with metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  Michael G. Anderson,et al.  Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function. , 2008, Experimental cell research.

[59]  M. Jeffers,et al.  Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011‐vcMMAE antibody‐drug conjugate , 2008, Molecular oncology.

[60]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[61]  S. Mohan,et al.  Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity , 2008, FEBS letters.

[62]  D. Hume,et al.  Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB. , 2008, Gene.

[63]  Z. Nagy,et al.  of Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium , 2008 .

[64]  K. Kishi,et al.  Osteoactivin fragments produced by ectodomain shedding induce MMP‐3 expression via ERK pathway in mouse NIH‐3T3 fibroblasts , 2007, FEBS letters.

[65]  P. Siegel,et al.  Osteoactivin/HGFIN: is it a tumor suppressor or mediator of metastasis in breast cancer? , 2007, Breast Cancer Research.

[66]  K. Ariizumi,et al.  Syndecan-4 Mediates the Coinhibitory Function of DC-HIL on T Cell Activation1 , 2007, The Journal of Immunology.

[67]  F. Pépin,et al.  Osteoactivin Promotes Breast Cancer Metastasis to Bone , 2007, Molecular Cancer Research.

[68]  M. Hameed,et al.  Role of human HGFIN/nmb in breast cancer , 2007, Breast Cancer Research.

[69]  Xiaojing Ye,et al.  The integrins , 2007, Genome Biology.

[70]  M. Jeffers,et al.  Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB , 2007, Cancer Chemotherapy and Pharmacology.

[71]  D. Hume,et al.  Gpnmb Is Induced in Macrophages by IFN-γ and Lipopolysaccharide and Acts as a Feedback Regulator of Proinflammatory Responses1 , 2007, The Journal of Immunology.

[72]  K. Ariizumi,et al.  DC-HIL is a negative regulator of T lymphocyte activation. , 2007, Blood.

[73]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[74]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[75]  M. Barbe,et al.  Osteoactivin acts as downstream mediator of BMP‐2 effects on osteoblast function , 2007, Journal of cellular physiology.

[76]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[77]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[78]  G. Riggins,et al.  Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients with Glioblastoma Multiforme , 2006, Clinical Cancer Research.

[79]  Damon L. Meyer,et al.  CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[80]  K. Sairyo,et al.  Osteoactivin upregulates expression of MMP-3 and MMP-9 in fibroblasts infiltrated into denervated skeletal muscle in mice. , 2005, American journal of physiology. Cell physiology.

[81]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[82]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[83]  J. Bonifacino,et al.  Signals for sorting of transmembrane proteins to endosomes and lysosomes. , 2003, Annual review of biochemistry.

[84]  K. Nagata,et al.  Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells. , 2003, Journal of hepatology.

[85]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[86]  D. Bigner,et al.  Bone-related Genes Expressed in Advanced Malignancies Induce Invasion and Metastasis in a Genetically Defined Human Cancer Model* , 2003, The Journal of Biological Chemistry.

[87]  G. Yehia,et al.  Hematopoietic growth factor inducible neurokinin-1 type: a transmembrane protein that is similar to neurokinin 1 interacts with substance P , 2003, Regulatory Peptides.

[88]  B. Weston,et al.  Structure–function relationships of the extracellular domain of the autosomal dominant polycystic kidney disease‐associated protein, polycystin‐1 , 2003, FEBS letters.

[89]  G. Gross,et al.  mRNA expression of the murine glycoprotein (transmembrane) nmb (Gpnmb) gene is linked to the developing retinal pigment epithelium and iris. , 2002, Brain research. Gene expression patterns.

[90]  K. Choi,et al.  Identification of the genes differentially expressed in human dendritic cell subsets by cDNA subtraction and microarray analysis. , 2002, Blood.

[91]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[92]  S. Saule,et al.  The AP-3-dependent targeting of the melanosomal glycoprotein QNR-71 requires a di-leucine-based sorting signal. , 2001, Journal of cell science.

[93]  K. Ariizumi,et al.  Molecular Cloning of a Dendritic Cell-associated Transmembrane Protein, DC-HIL, That Promotes RGD-dependent Adhesion of Endothelial Cells through Recognition of Heparan Sulfate Proteoglycans* , 2001, The Journal of Biological Chemistry.

[94]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[95]  K. Klinger,et al.  Strong homophilic interactions of the Ig-like domains of polycystin-1, the protein product of an autosomal dominant polycystic kidney disease gene, PKD1. , 2000, Human molecular genetics.

[96]  S. Saule,et al.  Characterization of a new melanocyte‐specific gene (QNR‐71) expressed in v‐myc‐transformed quail neuroretina. , 1996, The EMBO journal.

[97]  N. Ajubi,et al.  nmb, a novel gene, is expressed in low‐metastatic human melanoma cell lines and xenografts , 1995, International journal of cancer.

[98]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[99]  M. Fukuda,et al.  Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. , 1992, The Journal of biological chemistry.

[100]  Jun Yu Li,et al.  Gpnmb/osteoactivin, an attractive target in cancer immunotherapy. , 2012, Neoplasma.

[101]  K. Gelmon,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[102]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[103]  S. Adler,et al.  Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[104]  S. Popoff,et al.  Functional roles of osteoactivin in normal and disease processes. , 2010, Critical reviews in eukaryotic gene expression.

[105]  S. Popoff,et al.  Anti-osteoactivin antibody inhibits osteoblast differentiation and function in vitro. , 2003, Critical reviews in eukaryotic gene expression.

[106]  S. Marks,et al.  Identification and characterization of the genes encoding human and mouse osteoactivin. , 2003, Critical reviews in eukaryotic gene expression.

[107]  Jie Xu,et al.  Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts , 2001, Journal of cellular biochemistry.